Elekta AB (publ)

OM:EKTA B Stock Report

Market Cap: SEK 23.6b

Elekta Valuation

Is EKTA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EKTA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EKTA B (SEK63.1) is trading below our estimate of fair value (SEK125.03)

Significantly Below Fair Value: EKTA B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EKTA B?

Key metric: As EKTA B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EKTA B. This is calculated by dividing EKTA B's market cap by their current earnings.
What is EKTA B's PE Ratio?
PE Ratio21.3x
EarningsSEK 1.13b
Market CapSEK 23.61b

Price to Earnings Ratio vs Peers

How does EKTA B's PE Ratio compare to its peers?

The above table shows the PE ratio for EKTA B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.9x
GETI B Getinge
27.1x20.8%SEK 45.0b
ARJO B Arjo
17.9x25.1%SEK 8.9b
CEVI CellaVision
34.5x23.4%SEK 5.1b
ELOS B Elos Medtech
104.3xn/aSEK 5.7b
EKTA B Elekta
21.3x17.9%SEK 23.6b

Price-To-Earnings vs Peers: EKTA B is good value based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (45.9x).

Price to Earnings Ratio vs Industry

How does EKTA B's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EKTA B 21.3xIndustry Avg. 28.2xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EKTA B is good value based on its Price-To-Earnings Ratio (21.3x) compared to the European Medical Equipment industry average (28.2x).

Price to Earnings Ratio vs Fair Ratio

What is EKTA B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EKTA B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.3x
Fair PE Ratio27.9x

Price-To-Earnings vs Fair Ratio: EKTA B is good value based on its Price-To-Earnings Ratio (21.3x) compared to the estimated Fair Price-To-Earnings Ratio (27.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EKTA B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 63.10
SEK 75.57
+19.8%
24.0%SEK 127.00SEK 57.00n/a14
Nov ’25SEK 64.30
SEK 76.36
+18.8%
23.6%SEK 127.00SEK 57.00n/a14
Oct ’25SEK 70.00
SEK 76.21
+8.9%
23.8%SEK 127.00SEK 57.00n/a14
Sep ’25SEK 70.10
SEK 76.69
+9.4%
24.7%SEK 127.00SEK 57.00n/a13
Aug ’25SEK 66.40
SEK 76.31
+14.9%
24.9%SEK 127.00SEK 57.00n/a13
Jul ’25SEK 65.90
SEK 76.38
+15.9%
24.7%SEK 127.00SEK 57.00n/a13
Jun ’25SEK 86.15
SEK 84.08
-2.4%
24.4%SEK 127.00SEK 57.00n/a12
May ’25SEK 79.20
SEK 83.42
+5.3%
24.5%SEK 127.00SEK 57.00n/a12
Apr ’25SEK 80.70
SEK 86.00
+6.6%
23.7%SEK 127.00SEK 57.00n/a12
Mar ’25SEK 77.84
SEK 86.33
+10.9%
23.4%SEK 127.00SEK 57.00n/a12
Feb ’25SEK 78.54
SEK 86.67
+10.3%
23.4%SEK 127.00SEK 57.00n/a12
Jan ’25SEK 82.32
SEK 84.73
+2.9%
23.3%SEK 127.00SEK 57.00n/a11
Dec ’24SEK 82.08
SEK 84.91
+3.4%
23.7%SEK 127.00SEK 57.00n/a11
Nov ’24SEK 75.82
SEK 82.00
+8.2%
26.2%SEK 127.00SEK 53.00SEK 64.3011
Oct ’24SEK 74.42
SEK 83.30
+11.9%
26.6%SEK 127.00SEK 53.00SEK 70.0010
Sep ’24SEK 77.62
SEK 83.30
+7.3%
26.6%SEK 127.00SEK 53.00SEK 70.1010
Aug ’24SEK 85.18
SEK 83.20
-2.3%
26.2%SEK 127.00SEK 57.00SEK 66.4010
Jul ’24SEK 83.34
SEK 85.50
+2.6%
26.0%SEK 127.00SEK 57.00SEK 65.9010
Jun ’24SEK 81.62
SEK 83.40
+2.2%
25.5%SEK 127.00SEK 57.00SEK 86.1510
May ’24SEK 86.06
SEK 81.22
-5.6%
28.3%SEK 127.00SEK 57.00SEK 79.2010
Apr ’24SEK 79.08
SEK 81.22
+2.7%
28.3%SEK 127.00SEK 57.00SEK 80.7010
Mar ’24SEK 80.62
SEK 77.91
-3.4%
28.7%SEK 127.00SEK 57.00SEK 77.849
Feb ’24SEK 76.46
SEK 73.67
-3.7%
31.5%SEK 127.00SEK 52.00SEK 78.549
Jan ’24SEK 62.80
SEK 70.44
+12.2%
31.8%SEK 127.00SEK 52.00SEK 82.329
Dec ’23SEK 63.18
SEK 72.75
+15.1%
32.5%SEK 127.00SEK 52.00SEK 82.088
Nov ’23SEK 57.50
SEK 76.13
+32.4%
29.6%SEK 127.00SEK 55.00SEK 75.828

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Iconovo

SEK 79.9m

Develops and licenses inhalation medications in Sweden.

ICO

SEK 5.06

7D

2.4%

1Y

-45.1%

Dignitana

SEK 96.7m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

7D

3.5%

1Y

-45.9%

Mentice

SEK 536.9m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.90

7D

2.8%

1Y

-46.6%